Developer docs
API playgroundTry for free, no card

Search company profiles

Oncternal Therapeutics

Full company profile

uuid0003hoy

Namestring
Oncternal Therapeutics
Legal namestring
Oncternal Therapeutics
Websiteurl
oncternal.com
Company typeenum
Private
Founded yearint
2013
Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEncinitas, United States
HQ citystring
Encinitas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage oncology, cancer therapeutics, biopharmaceutical development, cell therapy development, oncology drug pipeline
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Oncology Therapeutics
Social media profiles2 records
Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Oncternal Therapeutics was a clinical-stage oncology company developing a diverse pipeline of treatments for cancers, with a focus on cell therapy approaches. The company is no longer operating as of 2025 and had not yet commercialized any approved product.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Oncternal Therapeutics was a clinical-stage oncology company based in San Diego, CA that is no longer operating as of 2025. The company was focused on developing cancer therapeutics but specific product names and details are not available from the provided source material. The company shutdown is noted in the 2025 Biotech Graveyard report alongside other cell therapy-focused biotechs that ceased operations.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing multi-tumor-associated antigen (TAA)-specific T-cell therapies for oncology. Comparable as a small clinical-stage oncology biotech focused on T-cell based modalities facing similar capital and regulatory headwinds.

TypeDirect peer
Description

Clinical-stage gene editing company developing allogeneic CAR T-cell therapies for oncology. Directly comparable as a clinical-stage oncology cell therapy biotech facing similar capital and clinical execution risks.

TypeDirect peer
Description

Clinical-stage cell therapy oncology company developing TCR-based therapies for solid tumors. Highly comparable as a small-cap clinical-stage oncology biotech with similar capital intensity and regulatory exposure; part of the broader 2025 biotech closure cohort.

TypeEmerging player
Description

Clinical-stage gene editing company developing CRISPR-based therapies including oncology applications. Comparable as a clinical-stage biotech with high capital intensity, though focused on gene editing rather than traditional oncology modalities.

TypeDirect peer
Description

Clinical-stage and recently commercial cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable as a cell therapy-focused oncology peer with similar clinical pipeline dynamics and capital needs.

TypeDirect peer
Description

Clinical-stage cell therapy oncology company developing off-the-shelf iPSC-derived NK and T-cell therapies. Directly comparable as a clinical-stage oncology peer focused on next-generation cell therapy modalities with similar capital requirements.

TypeDirect peer
Description

Clinical-stage allogeneic CAR T-cell therapy company for hematologic malignancies and solid tumors. Closely comparable in therapeutic modality (cell therapy for oncology), stage of development, and capital structure profile.

8Aeglea BioTherapeutics
TypeDirect peer
Description

Clinical-stage biotech focused on rare disease and oncology enzyme therapies that closed in 2025. Directly comparable as a small clinical-stage biotech that ceased operations due to similar financial and regulatory pressures.

TypeDirect peer
Description

Clinical-stage immunotherapy company developing T-cell engagers for oncology; was acquired by Merck in 2024. Comparable as a small clinical-stage oncology biotech that ultimately exited via acquisition rather than commercialization.

10Infinity Pharmaceuticals
TypeDirect peer
Description

Clinical-stage oncology company developing small molecule therapies for hematologic malignancies and solid tumors. Comparable as a small clinical-stage oncology biotech with similar capital structure and pipeline risk profile.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncternal Therapeutics

Clinical-Stage Oncology Therapeuticsoncternal.com

Oncternal Therapeutics firmographics

Firmographics
Name
Oncternal Therapeutics
Legal name
Oncternal Therapeutics
Website
https://oncternal.com
Company type
Private
Founded year
2013
Operating status
Closed
Headcount range
11–50 employees
Ownership category
akta.pro rank

Oncternal Therapeutics industry classification

Industry
Product category
Clinical-Stage Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Clinical-stage oncology
  • Cancer therapeutics
  • Biopharmaceutical development
  • Cell therapy development
  • Oncology drug pipeline

Where Oncternal Therapeutics is headquartered

Location

Headquarters

HQ city
Encinitas
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Oncternal Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

Oncternal Therapeutics product offering

Product offering

Core offering

Oncternal Therapeutics was a clinical-stage oncology company developing a diverse pipeline of treatments for cancers, with a focus on cell therapy approaches. The company is no longer operating as of 2025 and had not yet commercialized any approved product.

Product overview

Oncternal Therapeutics was a clinical-stage oncology company based in San Diego, CA that is no longer operating as of 2025. The company was focused on developing cancer therapeutics but specific product names and details are not available from the provided source material. The company shutdown is noted in the 2025 Biotech Graveyard report alongside other cell therapy-focused biotechs that ceased operations.

Differentiator

Problem solved

Functional benefit

Companies that use Oncternal Therapeutics

Customer profile

Ideal customer profiles1 record

Oncternal Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Oncternal Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Oncternal Therapeutics competitors and assessment

Company assessment

Direct peers

  • Marker Therapeutics: Clinical-stage cell therapy company developing multi-tumor-associated antigen (TAA)-specific T-cell therapies for oncology. Comparable as a small clinical-stage oncology biotech focused on T-cell based modalities facing similar capital and regulatory headwinds.
  • Precision BioSciences: Clinical-stage gene editing company developing allogeneic CAR T-cell therapies for oncology. Directly comparable as a clinical-stage oncology cell therapy biotech facing similar capital and clinical execution risks.
  • Adaptimmune Therapeutics: Clinical-stage cell therapy oncology company developing TCR-based therapies for solid tumors. Highly comparable as a small-cap clinical-stage oncology biotech with similar capital intensity and regulatory exposure; part of the broader 2025 biotech closure cohort.
  • Iovance Biotherapeutics: Clinical-stage and recently commercial cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable as a cell therapy-focused oncology peer with similar clinical pipeline dynamics and capital needs.
  • Fate Therapeutics: Clinical-stage cell therapy oncology company developing off-the-shelf iPSC-derived NK and T-cell therapies. Directly comparable as a clinical-stage oncology peer focused on next-generation cell therapy modalities with similar capital requirements.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR T-cell therapy company for hematologic malignancies and solid tumors. Closely comparable in therapeutic modality (cell therapy for oncology), stage of development, and capital structure profile.
  • Aeglea BioTherapeutics: Clinical-stage biotech focused on rare disease and oncology enzyme therapies that closed in 2025. Directly comparable as a small clinical-stage biotech that ceased operations due to similar financial and regulatory pressures.
  • Harpoon Therapeutics: Clinical-stage immunotherapy company developing T-cell engagers for oncology; was acquired by Merck in 2024. Comparable as a small clinical-stage oncology biotech that ultimately exited via acquisition rather than commercialization.
  • Infinity Pharmaceuticals: Clinical-stage oncology company developing small molecule therapies for hematologic malignancies and solid tumors. Comparable as a small clinical-stage oncology biotech with similar capital structure and pipeline risk profile.

Emerging players

  • Editas Medicine: Clinical-stage gene editing company developing CRISPR-based therapies including oncology applications. Comparable as a clinical-stage biotech with high capital intensity, though focused on gene editing rather than traditional oncology modalities.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Oncternal Therapeutics social profiles

Digital presence

Oncternal Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncternal Therapeutics leadership team

Management profile

Number of profiles

Oncternal Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncternal Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncternal Therapeutics

What does Oncternal Therapeutics do?

Oncternal Therapeutics was a clinical-stage oncology company developing a diverse pipeline of treatments for cancers, with a focus on cell therapy approaches. The company is no longer operating as of 2025 and had not yet commercialized any approved product.

Is Oncternal Therapeutics a public or private company?

Oncternal Therapeutics is a private company. It is classified as public and is currently closed.

When was Oncternal Therapeutics founded?

Oncternal Therapeutics was founded in 2013. It employs 11 to 50 people.

Where is Oncternal Therapeutics based?

Oncternal Therapeutics is headquartered in Encinitas, United States, in the North America region.

Who are Oncternal Therapeutics's main competitors?

Direct peers on record are Marker Therapeutics, Precision BioSciences, Adaptimmune Therapeutics, Iovance Biotherapeutics, Fate Therapeutics, Allogene Therapeutics, Aeglea BioTherapeutics, Harpoon Therapeutics and Infinity Pharmaceuticals. Editas Medicine is listed as an emerging player.

Does Oncternal Therapeutics have an API?

No public API is recorded for Oncternal Therapeutics.

What industry is Oncternal Therapeutics in?

Oncternal Therapeutics's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ETF Daily NewsOncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.comStockNews.com analysts initiated coverage of Oncternal Therapeutics with a hold rating on Friday. The stock opened at $0.53, with a 12-month range of $0.53 to $9.88 and a market cap of $1.56 million. The company's pipeline includes zilovertamab and ONCT-216 in Phase 1/2 trials.GlobeNewswireOncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic AlternativesOncternal Therapeutics announced termination of its clinical trials for ONCT-534 and ONCT-808, citing interim Phase 1 results showing no clinically meaningful improvements for ONCT-534 and one death for ONCT-808. The company will explore strategic alternatives, including asset sales, licensing, or a merger, and will reduce its workforce to preserve cash.BenzingaUS Stocks Mixed; Producer Prices Increase In August - SMART FOR LIFE INC by Smart for Life, Inc. (OTC:SMFU.S. stocks traded mixed on Thursday as the Dow Jones fell slightly while the NASDAQ and S&P 500 rose, amid news that U.S. producer prices increased by 0.2% in August. Individual equity performance varied significantly, with notable surges for Visionary Holdings Inc. following a Saudi investment deal and sharp declines for Fulcrum Therapeutics and Oncternal Therapeutics due to clinical trial failures and study terminations.Business InsiderOncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic AlternativesOncternal Therapeutics announced termination of its clinical trials for ONCT-534 and ONCT-808, citing interim Phase 1 results showing no clinically meaningful improvements for ONCT-534 and one death for ONCT-808. The company will explore strategic alternatives, including asset sales, licensing, or a merger, and will reduce its workforce to preserve cash.GlobeNewswireOncternal Therapeutics Provides Business UpdateOncternal Therapeutics reported Q2 2024 financial results and a business update, including $0.8 million grant revenue and $9.7 million in operating expenses. Its Phase 1/2 study of ONCT-534 for prostate cancer is advancing without dose-limiting toxicities, with initial data expected in Q3 2024. Cash of $21.4 million is projected to fund operations into Q1 2025.GlobeNewswireOncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial ResultsOncternal Therapeutics will report its fourth quarter and full year 2023 financial results after U.S. market close on March 7, 2024. Management will host a webcast at 2:00 p.m. PT to discuss the results. The company also highlighted its oncology programs, including ONCT-534 and ONCT-808.BenzingaOncternal Therapeutics Reports Patient Death In Mid-Stage Blood Cancer Study Treated With Second Dose LevOncternal Therapeutics reported a patient death in its Phase 1/2 Study ONCT-808-101 evaluating ROR1-targeting CAR T cell therapy ONCT-808 for relapsed or refractory aggressive B-cell lymphoma, with the fatality attributed to Grade 5 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) at the second dose level. The 80-year-old patient with bulky disease had no evidence of lymphoma found histologically in the initial autopsy report, while earlier data showed partial or complete responses at the initial dose cohort. The company has aligned with the FDA on protocol modifications including adjusted eligibility criteria and lower doses for future patients, and shares dropped 23.1% following the announcement.GlobeNewswireOncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial ResultsOncternal Therapeutics will report its third quarter 2023 financial results after U.S. market close on November 9, 2023, and will host a webcast at 2:00 p.m. PT to discuss the results. The company also announced its ongoing clinical programs, including studies for ONCT-534 and ONCT-808.BenzingaPromising Preclinical Results From Blood Cancer Propel Oncternal To Buy RatingHC Wainwright upgraded Oncternal Therapeutics from Neutral to Buy with a $2 price target, driven by promising preclinical data for the company's ROR1 CAR technology presented at the European Hematology Association meeting.